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license (http://creativenovo germ line mutations in the autosomal dominant genes such as APP, PSEN1, or PSEN2. We hy-
pothesized that negatively screened patients may harbor somatic variants in these genes.
Methods: We applied an ultrasensitive approach based on single-molecule molecular inversion
probes followed by deep next generation sequencing of 11 genes to 100 brain and 355 blood samples
from 445 sporadic patients with AD (.80% exhibited an early onset, ,66 years).
Results: We identified and confirmed nine somatic variants (allele fractions: 0.2%–10.8%): twoAPP,
five SORL1, one NCSTN, and oneMARK4 variants by independent amplicon-based deep sequencing.
Discussion: Two of the SORL1 variant might have contributed to the disease, the two APP variants were
interpreted as likely benign and the other variants remained of unknown significance. Somatic variants in
the autosomal dominantADgenesmaynot be a commoncauseof sporadicAD, including early onset cases.
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In the vast majority of the Alzheimer’s disease (AD)
cases, the disease is considered as a complex disorder with
a high genetic component as part of a multifactorial deter-
minism (for review, see [1]). However, AD can be inherited
as an autosomal dominant trait in a few families, with highly
penetrant pathogenic genetic variants in the APP, PSEN1, or
PSEN2 genes. These variants are sufficient to cause the dis-
ease, usually before the age of 66 years (early-onset Alz-
heimer’s disease [EOAD]). APP encodes the precursor of
the amyloid-b (Ab) peptide, the aggregation of which trig-
gers AD pathophysiology. Ab is generated following the
cleavage of APP by the b-secretase (encoded by BACE1)
and the g-secretase complex, the catalytic subunit of which
is encoded by PSEN1 or PSEN2. APP, PSEN1, and PSEN2
pathogenic variants are typically identified in families with
autosomal dominant EOAD, that is, at least two generations
showing at least one relative affected by EOAD. However,
patients with sporadic EOAD, that is, negative family his-
tory, have also been reported to carry a pathogenic variant
in these genes. Recently, 18/129 (14%) patients with spo-
radic EOAD and an age of onset before 51 years were re-
ported to present a pathogenic PSEN1 variant or an APP
duplication [2], although it was only 2/90 (2.2%) in patients
with a relatively later onset (51–65) [3]. Importantly, the mu-
tation occurred de novo in all 10 cases where DNA from the
unaffected parents was available [2]. In addition, whole
exome sequencing (WES) of EOAD patients and their unaf-
fected parents revealed de novo germline mutations in two
novel genes: VPS35 andMARK4 [4]. Overall, no pathogenic
variants are found in a majority of the patients with sporadic
AD undergoing screening for mutations in the known
genes [3–5].
It has been hypothesized for decades that post-zygotic
or even somatic, brain-specific, variants could cause the
disease in a proportion of sporadic AD patients but remain
undetected by standard sequencing techniques [6,7].
Recent advances in sequencing technologies currently
allow the accurate assessment of this hypothesis for the
first time (for review see [8]). For instance, deep
sequencing of APP, PSEN1, PSEN2, and MAPT was
recently applied to DNA isolated from the brain of 72
sporadic AD patients and 58 controls [9]. In another
study, WES was performed in brain-blood paired samples
of 17 sporadic AD patients (average depth of coverage:
60.8!) [10]. Although some somatic variants could be
detected, no clear pathogenic variant was identified in
these studies. Of note, the majority of the previously pub-
lished patients exhibited a late onset of AD (after
65 years). One could hypothesize that, similar to inherited
or de novo germline pathogenic variants, somatic variants
with high penetrance could be associated with an early
onset.
The first sequencing study of single neurons from nondi-
seased human brains recently revealed a high load of somaticgenetic variations. The number of somatic single nucleotide
variants could be as high as 1500 per neuronal genome
[11,12]. Interestingly, most of the variants that were
present in more than 5%–10% of the neurons were also
detected in tissues originating from all three embryonic
layers. This suggests that, if brain tissue is not available
for sequencing, sequencing DNA isolated from other
tissues including blood can allow the detection of post-
zygotic variants. Whatever the tissue of detection and allelic
ratios, assessing the pathogenicity of a given variant still re-
quires accurate interpretation. Regarding AD, we found one
example of a post-zygotic pathogenic PSEN1 variant de-
tected in 8% of the blood cells and 14% in the brain cells
of an EOAD patient [13].
Given the knowledge on seeding and spreading of neuro-
pathological lesions in AD brains [14], we hypothesized
that patients without a germline pathogenic variant in AD
autosomal dominant genes may harbor post-zygotic or so-
matic variants. The primary aim of this study was to assess
the presence of post-zygotic or somatic variants in APP,
PSEN1, and PSEN2 in patients with sporadic AD using
single-molecule molecular inversion probes (smMIPs).
The smMIP technology uses molecular barcodes (unique
molecular identifiers [UMI]) to allow for molecule-
specific deep sequencing. This is therefore an ultrasensitive
technique for the detection of low-level mosaics [15,16].
Our secondary aim was to assess the presence of post-
zygotic or somatic variants in 8 additional genes, namely
BACE1, NCSTN, APH1A, APH1B, PSENEN, SORL1,
VPS35, and MARK4. We applied molecule-specific deep
sequencing of this panel of 11 genes to DNA isolated
from blood (355 samples) or from brain (100 samples)
from 445 sporadic AD patients from France, the UK, and
the Netherlands (Table 1).2. Methods
We included 445 patients fulfilling the National Institute
on Aging–Alzheimer’s Association criteria for probable AD
or a definite diagnosis of AD (i.e., high AD neuropathologic
change according to National Institute on Aging–
Alzheimer’s Association criteria [17]) and a negative family
history, one positive control carrying a pathogenic PSEN1
variant, and 52 cognitively normal controls. All cases re-
cruited by the French National Reference Center for Young
Alzheimer Patients (CNRMAJ, Rouen, France) from multi-
ple French centers exhibited an early onset (,66 years), the
cases recruited by the Netherlands Brain Bank exhibited
either an early onset or, when the age at onset was not avail-
able, age at death was before 76 years, and cases recruited by
the Medical Research Council (MRC) brain bank were not
selected in the light of ages of onset; nine of them had an
early onset. Among cases, DNA was isolated from blood
(n 5 355 samples) and/or from brain tissue (n 5 100 sam-
ples) (Table 1, Supplementary Tables S1–4). DNA was
Table 1
Inclusion of cases for ultrasensitive sequencing
Study N patients (only blood)
N patients
(only brain)
N patients
(blood 1 brain)
Total N
patients
Mean age at
onset (range)
Mean age at
death (range)
Rouen CNRMAJ, France 347 2* 2y 351 54.42 (44–65) NA
MRC Brain Bank, UK 0 80 0 80 69.9 (53–82)z 85 (71–99)
Netherlands Brain Bank 0 8 6 14 56.4 (48–63)x 66.9 (57–75)
Total Total blood samples: 355 form 355 patients
Total brain samples: 100 from 98 patients
445
Abbreviation: MRC, Medical Research Council.
*One sample from cerebellum and one sample from frontal cortex for one patient, one sample from an unspecified region for the second patient.
yOne sample from cerebellum and one sample from frontal cortex in one patient, one sample from frontal cortex for the second patient.
zAmong the 29/80 patients with available information.
xAmong the 12/14 patients with available information.
G. Nicolas et al. / Alzheimer’s & Dementia 14 (2018) 1632-16391634isolated from blood for all 52 controls. All cases except those
from the Netherlands Brain Bank (Netherlands lnstitute for
Neuroscience, Amsterdam; open access: www.brainbank.
nl) were previously negatively screened for germline patho-
genic variants in APP, PSEN1, and PSEN2, either by whole
exome or by Sanger sequencing [18,19]. All participants or
their legal representatives provided written informed
consent for genetic analyses and/or for a brain autopsy and
for the use of the material and clinical information for
research purposes. Ethical approval for the genetic
analysis of postmortem brain tissue was obtained from the
ethical review board of each participating center. For
details on inclusion, see Supplementary Methods.
We designed and set up an ultrasensitive smMIP assay
aiming at sequencing the coding regions of 11 genes
including the three autosomal dominant AD genes (APP,
PSEN1, and PSEN2), the genes recently identified in a
trio-exome sequencing study in sporadic EOAD cases
VPS35 and MARK4, the risk factor gene SORL1, and, as
an exploratory study, BACE1 encoding the b-secretase,
and the genes encoding the other members of the g-secre-
tase complex NCSTN, PSENEN, APH1A, and APH1B. Af-
ter rebalancing the concentration of the smMIP pool
following a first test run, we performed four independent
runs of sequencing on an Illumina NextSeq sequencer
(runs A-D, see Supplementary Methods). All cases, the
positive control and 16 of the cognitively normal controls
were assessed with two independent polymerase chain re-
action (PCR) amplifications of the smMIP capture, while
the remaining 32 controls were amplified once.
Raw bioinformatics data were processed following three
distinct pipelines, all three contained a PCR duplicates
removal step using the UMI information: BWA-GATK,
Seqnext (JSI medical systems), and an in-house pipeline
based on the pileup format as generated by SAMtools.
Briefly, the latter pipeline consisted in the computation of
a base-specific error rate per run as published previously
[16], based on pileup formats, followed by the calling of
candidate somatic variants significantly deviating from
the base-specific error rate, for both PCR duplicates, fol-lowed by manual curation. Candidate somatic variants
were confirmed by independent amplicon-based deep
sequencing.
Detailed methods on smMIP assay design, library prepa-
ration, sequencing, bioinformatics analyses including DNA
contamination assessment, and amplicon deep sequencing
are provided in Supplementary Methods.3. Results
3.1. Coverage statistics
After removal of PCR duplicates thanks to the UMI, the
average single-molecule coverage was 1027! per smMIP
(seven failed samples were excluded). Regarding the three
autosomal dominant AD genes APP, PSEN1, and PSEN2,
the single-molecule average coverage at all bases of interest
(coding exons 6 2 bp; 3101 bp) was 2576!; 97.6% of the
bases of interest were covered by at least 100 unique reads
among more than 97% of the samples.3.2. Identification and validation of somatic variants
We detected nine candidate somatic variants in nine pa-
tients (seven blood samples, two brain samples; Table 2).
We performed an independent validation by amplicon deep
sequencing, using PCR followed by Ion Torrent Personal
Genome Machine sequencing (average depth of coverage
of all nine amplicons: 60,104!) and validated all nine var-
iants as true somatic events (Table 2, Supplementary Table
S5). The variant allelic fractions (VAFs) ranged from
0.22% to 10.8% and were in similar ranges after amplicon
deep sequencing. Six somatic variants were novel, and three
were present in the gnomAD database with very low fre-
quencies (3, 12, and 14 allele counts, respectively) [20].
Two of these variants were missense variants in exons 6
and 7 the APP gene, respectively. However, as all known
pathogenic variants are located in the coding sequence of
the Ab peptide or its boundaries (exons 16-17), these vari-
ants were interpreted as likely benign regarding their
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G. Nicolas et al. / Alzheimer’s & Dementia 14 (2018) 1632-1639 1635putative contribution to AD. No candidate somatic variant
was detected in PSEN1 and PSEN2 across all samples.
The other somatic variants were located in SORL1 (n5 5,
including one missense, three synonymous, and one intronic
variant), NCSTN (n5 1, missense) andMARK4 (n5 1, syn-
onymous). One of the SORL1 somatic variants
(NM_003105.5:c.2207G.A, VAF 5 3.61% in blood) was
annotated as missense and predicted damaging by 3/3 in sil-
ico prediction tools amongMutation Taster, PolyPhen 2, and
SIFT (strictly damaging). The other SORL1 somatic variants
were synonymous (n5 3) or intronic (n5 1). Of note, one of
the synonymous variants was predicted to strongly enhance
a cryptic 50 splicing site (NM_003105.5:c.2475G.A,
VAF 5 0.36% in blood, MaxEntScan score 1202%) and
hence might disrupt the SORL1 coding sequence. The in-
tronic SORL1 mutation was close to a canonical splice site
(c.5605-3C.T) although splicing prediction tools suggested
a weak or absent effect.
In four samples, from one particular sequencing run,
additional variants were identified with allelic fraction in
the ranges of 1% to 3%. However, we considered these re-
sults as putative DNA contamination because the variants
were known as common polymorphisms in variant databases
(minor allele frequency . 1%), each putatively contami-
nated sample harbored at least two of these variants, and
they were detected as germline heterozygous or homozy-
gous in other samples from the same run, all samples
initially belonged to a single plate, before capture. The pres-
ence of DNA contamination was further assessed using the
same technique based on the pileup formats as for candidate
somatic variants, in all four runs, taking into account nucle-
otide changes that correspond to known SNPs. No additional
contamination was identified.3.3. Interpretation of probably germ line APP, PSEN1,
and PSEN2 variants
After variant calling by GATK and SeqNext, followed by
annotation and variant interpretation, we accurately detected
the probably germline heterozygous PSEN1 variant included
as a positive control in one brain sample from theMRC brain
bank (Supplementary Table S6). No probable germline
(allelic ratio 25%–100%) variant was rated as pathogenic
or likely pathogenic in these genes in cases. Of note, we
confirmed the presence of four known heterozygous
missense variants of unknown significance (class 3
following the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology rec-
ommendations [21], one in PSEN1, and three in PSEN2) in
two French patients (blood samples) and two patients from
the MRC brain bank (brain samples) (Supplementary
Table S6), including the p.V101M PSEN2 variant that has
been previously reported in the brain of a patient with spo-
radic AD [9], also as a probably germline variant. Additional
variants were detected in all three genes, but they were
G. Nicolas et al. / Alzheimer’s & Dementia 14 (2018) 1632-16391636classified as benign or likely benign based on their predicted
effect, variant frequencies in controls, and previous reports.3.4. Probable germline VPS35 and MARK4 variants
VPS35 and MARK4 are candidate genes for autosomal
dominant EOAD given the observation of de novo germline
mutations in two sporadic EOAD patients, and subsequent
in vitro studies showing biochemical defects consistent
with AD pathophysiology [4].
We identifiedone rarenonsynonymousvariant inVPS35 and
five inMARK4, all with a VAF suggestive of a germline origin
(Supplementary Table S7). Of note, the c.2320C.A,
p.Leu774Met VPS35 variant was found in both the brain and
blood tissues in a patient from the Netherlands Brain Bank.
This variant has already been detected in 2/863 cases (Austrian
andGerman patients) with early onset Parkinson disease and 2/
1014 controls [22]. It is located in the same C-terminal domain
of the protein as the p.Asp620Asn Parkinson disease–causing
mutation and the p.Leu625Pro deleterious de novo germline
variant found in an EOAD patient [4,22]. Although they
mapped very close to each other in the protein sequence, the
latter two variants had distinct consequences on the retromer
complex function in vitro, which is consistent with their
association with distinct phenotypes. The p.Leu774Met
variant mapped 3’ from this region and was not predicted to
have a strong impact on protein stability. Interestingly, the
father of the proband was known to suffer from Parkinson
disease although without dementia (no clinical details or
DNAavailable). This variant remains of unknown significance.
In MARK4, one of the variants was predicted benign and
was inherited from an unaffected parent (c.1553C.T,
p.(Pro518Leu)). One variant was predicted damaging by
the three assessed in silico prediction tools but was exclu-
sively found in one of the unaffected parents (c.88G.T,
p.(Gly30Cys)). The other three variants were found in cases
only. Although they were predicted damaging by all three in
silico prediction tools (c.1033C.T, p.(Arg345Trp), French
patient, blood sample) or by 1 or 2/3 (c.1982G.A,
p.(Ser661Asn); c.230G.A, p.(Arg77Gln); MRC patients,
brain samples), no conclusion can be drawn due to the fact
that they were most probably present in as heterozygous
germline and that no segregation data are available.3.5. Probable germline SORL1 variants
We found 15 protein-truncating or missense SORL1 var-
iants that were considered as strictly damaging (i.e., pre-
dicted damaging by the three in silico prediction tools
PolyPhen 2, SIFT, and Mutation Taster), in 17 patients and
no control (Supplementary Table S8). These categories of
variants have been shown to increase the risk of EOAD
[18,23]. All VAF were in ranges suggesting that they were
present in the germline. Among them, 12 variants present
in 14 patients were already reported in previous WESstudies [18,23], and three variants (two novel) were found
in novel patients, identified from brain tissues.3.6. Probable germline variants in BACE1 and genes
encoding members of the g-secretase complex
We detected 11 rare nonsynonymous variants in 12 pa-
tients in BACE1 (n 5 2), NCSTN (n 5 4), APH1A (n 5 1),
APH1B (n 5 3), and PSENEN (n 5 1) (Supplementary
Table S9). These variants were detected in 10 blood samples
and two brains samples and the VAF suggested their germ-
line origin. All but one were missense. A frameshift variant
was detected in the APH1B gene. However, this gene is not
under strong constraint against loss of function, similar to
PSEN2, judging by the probability of loss of function intol-
erance established from Exome Aggregation Consortium
data [20]. All were detected in patients.4. Discussion
In this study, we screened 11 genes for somatic mutations
in 355 blood samples and 100 brain samples from 445 pa-
tients with AD, of which 372 (83.5%) exhibited an early
onset (,66 years). In total, we identified nine somatic vari-
ants with variant fractions ranging from 0.2% to 10.8%.
These variants were detected in multiple DNA copies and
are more likely clonal than recurrent mutational events.
The coverage statistics, together with the validation of all
variants detected, including all six with an allelic ratio below
than 1% (range 0.22%–0.48%), support the ultrasensitivity
of our detection method. We did not find any candidate
post-zygotic or low-level somatic variant in the three estab-
lished autosomal dominant AD-causative genes APP,
PSEN1, and PSEN2 that could be interpreted as likely path-
ogenic. Given the high sensitivity of the assay, we consider
our screen as negative regarding likely pathogenic variants
in the coding region of these genes.
We could find only one example in the literature of an AD
patient with a post-zygotic causative variant in PSEN1 [13].
In this study, a patient with EOAD starting at the age of
27 years was found to have inherited a pathogenic mutation
in PSEN1 from her affected mother, who presented a disease
onset at the age of 52. The mutation was present in 8% of the
mother’s blood cells and 14% of her brain cells, suggesting
that the mutation occurred as a post-zygotic event in the
mother and that it was present in variable proportions of cells
in multiple tissues including the mother’s oocytes [13]. Of
note, the majority of our patients presented an early onset
of sporadic AD (83.5%), and therefore this is the largest se-
ries of sporadic EOAD patients screened for pathogenic so-
matic variants causative for AD to date. The assessment of
the somatic variant hypothesis in sporadic AD has been per-
formed only recently, using deep sequencing [9] or brain-
blood paired WES [10], in patients with a later onset on
average than in our study. To our knowledge, our screen is
the first to leverage UMIs to allow single-molecule tracing
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somatic variants in APP, PSEN1, and PSEN2 are not a com-
mon cause of sporadic AD, even in patients with an early
onset. We acknowledge, however, that somatic variants
might still be present as even more rare events in brain re-
gions, which have not been assessed. Indeed, this and previ-
ous studies focused only on one or two brain regions per
individual. The interpretation of putative region-specific var-
iants may however be difficult. In addition, our assay did not
allow the identification of mosaic copy number variations.
As part as our gene panel, we also sequenced the VPS35
andMARK4 genes. They were each previously hit by one de
novo germline mutation in sporadic EOAD patients [4]. The
effect of these variants was studied in vitro, and the location
where the mutation occurred in the protein could be highly
specific, given the results of functional assays. Despite the
identification of a synonymous somatic variant in MARK4
(VAF 5 0.43%), we could not identify any putatively
damaging variant in the corresponding exons as a germline
or a somatic variant.
Germline protein truncating and rare missense predicted
to be strictly damaging SORL1 variants significantly increase
the risk of EOAD [18,23]. We detected five SORL1 somatic
variants (VAF ranging from 0.63% to 7.91%). Among
them, one was missense and classified as strictly damaging.
It was detected in a blood sample of an EOAD patient and
could, if present in the brain tissue, contribute to the
genetic determinism of AD in this patient. Among the
other SORL1 somatic variants, one was predicted to
enhance a cryptic 50 splicing site and could disrupt SORL1
coding sequence. If so and if present in the brain tissue, it
could also contribute to the genetic determinism of AD in
this patient. SORL1 rare damaging variants were originally
identified in EOAD probands with a positive family history
of EOAD, with no pathogenic APP, PSEN1, or PSEN2
variant [24]. However, the paucity of segregation data still
precludes the classification of SORL1 as a putative Mende-
lian gene and association studies showed a role as a risk factor
(for review, see [1]). Our results suggest that the other genes
TREM2 and ABCA7, the rare damaging variants of which
having been shown to increase the risk of AD, should also
be screened for post-zygotic and somatic variation.
We included in our assay the candidate genes BACE1 en-
coding the b-secretase and the other genes encoding the other
proteins from the g-secretase complex (in addition to PSEN1
and PSEN2). We detected one somatic variant in NCSTN,
which was present in w22% of the sequenced cells from
the blood of one EOAD patient (VAF5 10.8%). This variant
introduced a missense that was predicted damaging by SIFT
but not by PolyPhen2 and Mutation Taster. It has been
observed in 12 individuals from the gnomAD database (mi-
nor allele frequency 5 4.9! 1025) [20]. The visualization
of the BAM files of the three variant carriers available in
the gnomADwebsite suggested that this variant was compat-
ible with a heterozygous variant with germline origin, which
is not consistent with the hypothesis of a damaging effectwhen carried as a post-zygotic event. Interestingly, we also
detected 12 variants in 11 patients that were probably present
in the germline. All were detected in patients. To our knowl-
edge, there is no evidence of rare variants in these genes
segregating in families further than by chance, or of a signif-
icant association of rare variants with AD. This studywas not
designed as an association study, and these genes were not re-
ported among the latest large association studies including
our own data from France [18]. By including these genes
that play a key role in Ab generation in the context of the
g-secretase complex, we made the hypothesis that the
absence of damaging variants segregating in families in the
literature could be explained by a putative intolerance
(abnormal development, lethality, and other diseases). Post-
zygotic damaging variants might be better tolerated and pu-
tatively increase the generation of Ab through increased b or
g-cleavage or its regulation. We did not find such candidates
somatic variants in our study. These genes remain biological
candidates currently lacking genetic evidence.
In conclusion, we used single-molecule deep sequencing
in brain and/or blood samples of 445 patients with sporadic
AD and could detect nine somatic variants with allelic ratios
as low as 0.2%. Although we detected a few putatively
damaging SORL1 somatic variants, we did not detect any
candidate post-zygotic or somatic variant that could be inter-
preted as pathogenic or likely pathogenic in the three known
autosomal dominant AD genes. Our results, together with a
previous report [9], challenge the hypothesis that somatic
mutations in key AD genes would cause a significant propor-
tion of AD with a sporadic presentation. We conclude that
somatic variation in these genes is most likely not a frequent
cause of sporadic AD.Acknowledgments
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1. Systematic review: Attention toward the somatic
variant hypothesis is growing. This hypothesis states
that a proportion of patients with Alzheimer’s disease
could have developed the disease because of somatic
mutations in the brain, leading to pathological le-
sions that would later spread into the brain. However,
we could find only one published example. Advances
in sequencing technologies allow the assessment of
this hypothesis since very recently only.
2. Interpretation: We assessed this hypothesis using an
ultrasensitive molecule-specific deep sequencing
approach in young patients. Nine somatic variants
were identified, and some of them could have
contributed to the development of the disease. How-
ever, no pathogenic variant was found in the known
autosomal dominant genes, thus challenging the hy-
pothesis.
3. Future directions: Other techniques could be applied
to detect other genomic variations such copy number
variations. In addition, genetic variants in a small
proportion of cells - not detectable by our technique
- could be a future research direction.References
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